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Simultaneous determination of warfarin and 7-hydroxywarfarin 
in rat plasma by HPLC-FLD
In this study, high-performance liquid chromatography 
with fluorescence detection (HPLC-FLD) has been used for 
the first time, for direct determination of warfarin and its 
major metabolite, 7-hydroxywarfarin, in rat plasma. The 
simple and sensitive method was developed using Fortis® 
reversed-phase diphenyl column (150 × 4.6 mm, 3 μm) and 
a mobile phase composed of phosphate buffer (25 mmol L–1)/
methanol/acetonitrile (70:20:10, V/V/V), adjusted to pH 7.4, 
at a flow rate of 0.8 mL min–1. The diphenyl chemistry of the 
stationary phase provided a unique selectivity for separat-
ing the structurally related aromatic analytes, warfarin and 
7-hydroxywarfarin, allowing their successful quantifica-
tion in the complex plasma matrix. The method was linear 
over the range 0.01–25 μg mL–1, for warfarin and 7-hydroxy-
warfarin, and was found to be accurate, precise and selec-
tive in accordance with US FDA guidance for bioanalytical 
method validation. The method was sensitive enough to 
quantify 0.01 μg mL–1 of warfarin and 7-hydroxywarfarin 
(LLOQ) using only 100 μL of plasma. The applicability of 
this method was demonstrated by analyzing samples ob-
tained from rats after oral administration of a single warfa-
rin dose, and studying warfarin and 7-hydroxywarfarin 
pharmacokinetics. 
Keywords: warfarin, 7-hydroxywarfarin, high-performance 
liquid chromatography-fluorescence detection, rat plasma, 
pharmacokinetics
Warfarin is the most commonly prescribed anticoagulant in the world (1). It is a vita-
min K antagonist used to treat and prevent blood clots and is indicated for the treatment 
of atrial fibrillation and deep vein thrombosis (2). Warfarin is a racemic mixture of 3-(α-ace-
tonylbenzyl)-4-hydroxycoumarin (Fig. 1). The S-enantiomer exhibits 2–5 times higher anti-
coagulant activity than the R-enantiomer in humans (3–5). It is absorbed rapidly from 
gastrointestinal tract following oral administration, reaching peak plasma concentration 
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after 4 h (5, 6). The effective half-life after oral administration ranges from 20 to 60 h with 
92 % of the dose excreted in the urine. The half-life of the R-enantiomer is longer (37–89 h) 
than that of the S-enantiomer (21–43 h) (6). The two enantiomers are stereoselectively 
 metabolized by hepatic CYP450 microsomal enzymes (7). S-warfarin metabolism by 
CYP2C9 yields 6- and 7-hydroxylated metabolites, whereas R-warfarin metabolism by 
CYP1A1, 1A2 and 3A4 yields 6-, 8-, and 10-hydroxylated metabolites (8–10) (Fig. 1). Overall, 
7-hydroxywarfarin is the most predominant metabolite of warfarin in humans (11–13). Several 
studies indicated that alteration of warfarin pharmacokinetics (PK) following the admini-
stration of CYP450 inhibitors can enhance the anticoagulant activity and thus increase the 
risk of bleeding as a result of elevation of warfarin plasma concentration (14, 15). The likeli-
hood of such interaction is further increased due to the narrow therapeutic index and 
 extensive protein binding (99.83 %) of warfarin (1), in addition to the significant inter-indi-
vidual variation in drug response. Determination of metabolic ratios of warfarin/7-hydroxy-
warfarin can provide valuable information about potential interaction of warfarin with 
drugs or diet at the metabolic level where many warfarin interactions occur. To investigate 
these interactions, sensitive and selective methods are required for the simultaneous 
quantification of warfarin and its 7-hydroxywarfarin metabolite in plasma. 
Various methods have been reported for the quantitation of racemic warfarin and its 
main metabolites in biological samples using high-performance liquid chromatography 
(HPLC) coupled with a variety of detectors including ultraviolet (UV) (16–19), fluorescence 
(FLD) (19–21) and mass spectrometric detector (MS) (13, 22–26). Although LC-MS/MS methods 
are very selective and sensitive, the high capital cost of the MS detector presents a major 
limitation. HPLC-UV is a cheaper option, but it lacks the sensitivity and selectivity 
 required for the analysis of the low plasma levels of warfarin and its metabolites. The 
 inherited selectivity and sensitivity of fluorescence detector were exploited in few studies 
for the measurement of warfarin and its hydroxylated metabolites in biological samples 
including urine (19), plasma (20) and microbial cultures (27). Takahashi et al. (19) quantified 
warfarin in human plasma or 7-hydroxywarfarin in urine by HPLC with UV or fluorescent 
detection. Lomonaco et al. (20) developed and validated HPLC-FLD method for simultaneous 
quantification of warfarin and warfarin alcohols (ketone warfarin). Using post-column pH 
switching, Lee et al. (28) used a normal phase HPLC-FLD method for quantifying racemic 
warfarin and its major metabolites in plasma. None of the previously described HPLC- 
-FLD methods, however, allowed for direct and simultaneous quantification of warfarin 
and 7-hydroxywarfarin in plasma. 
Fig. 1. Warfarin structure showing hydroxylation sites by cytochrome P450.
345
A. Zayed et al.: Simultaneous determination of warfarin and 7-hydroxywarfarin in rat plasma by HPLC-FLD, Acta Pharm. 70 (2020) 
343–357.
 
In this study, we describe the development and validation of the first HPLC-FLD 
method for simultaneous and direct determination of warfarin and 7-hydroxywarfarin in 
in vivo small samples (100 μL) of rat plasma. Unlike other HPLC-FLD methods, the samples 
didn’t require sample derivatization or post-column manipulation to detect warfarin and 
7-hydroxywarfarin in plasma, which is a major advantage for the routine analysis of bio-
logical samples. The method was applied successfully to assess the PK of warfarin in rats 
following oral administration of a single warfarin dose. 
EXPERIMENTAL
Materials
Racemic warfarin, 7-hydroxywarfarin and 10-hydroxywarfarin were purchased from 
Sigma-Aldrich (USA). 4-Hydroxywarfarin, 6-hydroxywarfarin and warfarin alcohol were 
purchased from Toronto Research Chemicals (Canada). Naproxen (purity 99.2 %) was 
kindly supplied as a gift from Hikma Pharmaceuticals (Jordan). HPLC grade acetonitrile, 
ethylacetate and methanol were purchased from Fisher Scientific (USA). Phosphate buffer, 
potassium monobasic and dibasic, were purchased from Sigma-Aldrich.
Preparation of standard solutions
A stock solution of each warfarin and 7-hydroxywarfarin was prepared by dissolving 
5.0 mg of the reference standard in 10 mL methanol in a volumetric flask to produce a 
concentration of 500 μg mL–1. Working solution (50.0 μg mL–1) of each, warfarin and 7-hy-
droxywarfarin, was prepared in methanol after dilution. A stock solution of naproxen, 
used as an internal standard, was prepared by dissolving 5.0 mg of naproxen in 25 mL 
methanol to produce a concentration of 200 μg mL–1.
The working solutions were used to prepare eight plasma calibration standards within 
a concentration range 0.01–25 μg mL–1 for both warfarin and 7-hydroxywarfarin. Appropriate 
amounts of the standards were used to spike drug free plasma (blank plasma) to produce 
the following calibration standard concentrations: 0.01, 0.05, 0.10, 0.50, 1.0, 5.0, 10.0 and 
25.0 μg mL–1. Quality control (QC) samples were prepared in plasma at four concentration 
levels for both warfarin and 7-hydroxywarfarin: 20.0 μg mL–1 (QC-high), 1.0 μg mL–1 (QC-mid), 
0.05 μg mL–1 (QC-low) and 0.01 μg mL–1 (LLOQ). Calibration and quality control standards 
were stored in propylene tubes at –40 °C.
Instrumentation
Quantification of warfarin and 7-hydroxywarfarin was carried out on a Shimadzu 
10A VP HPLC system (Japan) equipped with fluorescence detector adjusted at excitation 
and emission wavelengths of 310 nm and 390 nm, resp. Data acquisition and integration 
were performed using a Shimadzu CLASS-VP v. 6.12 software. Chromatographic separa-
tion was achieved using Fortis® reversed-phase diphenyl column (150 × 4.6 mm, 3 μm) 
(Fortis Technologies Ltd., UK) protected by a guard cartridge (4.0 × 4.6 mm). The mobile 
phase consisted of phosphate buffer (25 mmol L–1)/methanol/acetonitrile (70:20:10, V/V/V) 
(pH 7.4) and delivered at a flow rate of 0.8 mL min–1 in the isocratic mode.
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Plasma samples (100 μL) containing warfarin and 7-hydroxywarfarin were spiked 
with internal standard solution (20 μL). The samples were acidified by adding 0.05 mol L–1 
acetic acid (10 μL) and vortex-mixed for 30 s before extraction with ethylacetate (3 mL) for 
2 min using a vortex-mixer. After centrifugation at 4000 rpm for 10 min, the upper organic 
phase (2.7 mL) was transferred into clean glass tube and evaporated under a stream of 
 nitrogen at 40 °C. The residue was then reconstituted with 150 μL mobile phase and 50 μL 
was then injected into the HPLC system for quantifying warfarin and 7-hydroxywarfarin.
Method development 
During the method development, different column chemistries were tested with dif-
ferent mobile phase compositions to achieve a chromatographic separation suitable for 
simultaneous quantification of warfarin and 7-hydroxywarfarin in plasma. Water, metha-
nol and acetonitrile in different ratios were tested as solvents in the mobile phase, with 
formic acid or phosphate buffer for pH adjustment. The stationary phases tested during 
method development were C8, C12, C18 and diphenyl with various particle sizes and col-
umn dimensions. The optimized method was then validated in accordance with US Food 
and Drug Administration guidance for bioanalytical method validation (29).
Analytical method validation 
Linearity. – Linearity was evaluated by examining six calibration curves with eight 
non-zero concentrations of warfarin and 7-hydroxywarfarin (0.01–25.0 μg mL–1). Peak area 
ratios of warfarin or 7-hydroxywarfarin to internal standard was plotted against concen-
trations of warfarin and 7-hydroxywarfarin using 1/x linear regression weighting factor. 
Coefficient of determination (R2) equal to or greater than 0.99 was considered as an accept-
able evidence of linearity. 
Accuracy and precision. – Intra-day accuracy and precision were evaluated by examin-
ing plasma samples spiked with warfarin and 7-hydroxywarfarin at four concentration 
levels (LLOQ: 0.01 μg mL–1, QC-low: 0.05 μg mL–1, QC-mid: 1.0 μg mL–1, and QC-high: 20.0 
μg mL–1). The run consisted of 24 spiked samples (6 replicates for each concentration) plus 
calibration standard samples prepared in the same day. Inter-day accuracy and precision 
were assessed by examining spiked plasma samples of warfarin and 7-hydroxywarfarin 
at four concentration levels mentioned above, each run in six replicates, on three consecu-
tive days.
Peak areas were calculated and analyzed against a calibration curve that was pre-
pared alongside each batch. To calculate intra-day and inter-day accuracy, the relative error 
(er) at each QC concentration level was estimated. To calculate intra-day and inter-day 
precision, the relative standard deviation (RSD) at each QC concentration level was deter-
mined. er and RSD values within ± 15 %, not exceeding 20 % for LLOQ, were considered as 
evidence of acceptable accuracy and precision, resp. (29).
Sensitivity. – Sensitivity was assessed by examining six replicates at LLOQ (0.01 
μg mL–1). Acceptance criteria for warfarin and 7-hydroxywarfarin were that their response 
347
A. Zayed et al.: Simultaneous determination of warfarin and 7-hydroxywarfarin in rat plasma by HPLC-FLD, Acta Pharm. 70 (2020) 
343–357.
 
at the LLOQ should be ≥ 5 times their response of the zero calibrator (blank sample) with 
er and RSD ≤ 20 %. LLOQ was defined as the lowest non-zero standard analyte concentra-
tion on the calibration curve. Limit of detection (LOD) is defined as an analyte concentra-
tion resulting in a signal-to-noise ratio of 3:1.
Selectivity. – The method selectivity is the assessment for interference by cross-reacting 
molecules, concomitant medications and bio-transformed species. The selectivity was 
 assessed by analyzing blank plasma samples from six different animals to show that plasma 
sources did not contribute to either the analytes or the internal standard responses. Each 
sample was analyzed for potential interferences from endogenous substances such as 
 endogenous matrix components, metabolites and decomposition products which should 
be absent at the retention time of warfarin, 7-hydroxywarfarin and the internal standard 
naproxen. A mixture of standard solutions containing warfarin and its main metabolites 
(4-, 6-, 7-, 10-hydroxywarfarin and warfarin alcohol) was used to asses if the method is able 
to distinguish warfarin and 7-hydroxywarfarin from other potential metabolites.
Carryover. – Carryover is the appearance of an analyte in a sample from a previous 
one. Impact of carryover on the accuracy of the study was assessed by injecting blank 
samples after a calibration standard sample with the highest concentration. Carryover in 
the blank sample following the high concentration standard should not be greater than 
20 % of LLOQ and 5 % for the internal standard.
QC samples were interspersed with study samples before and during processing and 
analysis. A batch or batches in an analytical run may be rejected if the QC samples fail to 
meet the acceptance criteria. The total number of QCs was at least 5 % of the total samples 
analyzed but not less than 6 samples, whichever number is greater. Duplicate QC-low, 
 QC-mid, and QC-high were used in all distinct processing batches within a run. Not less 
than 50 % of QCs per level should be ± 15 % of their nominal concentration.
Stability of warfarin and 7-hydroxywarfarin in working standards and in plasma was 
investigated in previous reports (13, 20, 22).
Pharmacokinetic study
Six male Sprague-Dawley (SD) rats, weighing 150–250 g, were supplied from animal 
house, Jordan University of Science and Technology (JUST, Irbid, Jordan). The rats were 
maintained in a clean room at a temperature of 25 ± 2 °C, with a 12-h light-dark cycle and 
50 % relative humidity. The experiments were carried out during the light cycle. The animals 
were acclimatized to laboratory conditions for a week prior to beginning of the  experiments, 
and they were provided with filtered tap water and a standard rat chow diet ad libitum. All 
experimental procedures were carried out under the approval by the Animal Care and Use 
Committee (ACUC) of Jordan University of Science and Technology. 
The SD rats were fasted 12 h before the beginning of the experiments with access to 
filtered tap water ad libitum. A single dose of a warfarin solution (4 mg mL–1 in DMSO) was 
administered orally to each animal at a dose of 2.0 mg kg–1. Blood samples (200–300 μL) 
were collected from the tail instantly before warfarin treatment and at 0.5, 1, 2, 3, 4, 6, 8, 24, 
30, 48, 54, 72, 96 and 120 h after warfarin treatment. Blood samples were immediately 
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treated by centrifugation at 13,000 rpm for 5 min, and 100 μL plasma samples were trans-
ferred to sample tubes and kept frozen at –80 °C until subsequent analysis.
A non-compartmental pharmacokinetic analysis was performed using WinNonlin 5.3 
software (Pharsight Co., Mountain View, CA, USA). The non-compartmental pharmacoki-
netic parameters determined were peak plasma concentration (Cmax), time to reach peak 
plasma concentration (tmax), terminal half-life (t1/2), apparent total clearance (CL/F), appar-
ent volume of distribution of terminal phase (Vd/F), total area under the concentration- 
-time curve AUC0µ, total area under the first moment curve (AUMC0µ) and mean residence 
time (MRT).
RESULTS AND DISCUSSION
Method development and optimization
In order to develop selective and sensitive chromatographic separation for determina-
tion of plasma levels of warfarin and 7-hydroxywarfarin in vivo, several issues had to be 
addressed. Although fluorescence detection is more selective than UV, several fluorescent 
species, such as some warfarin metabolites, are expected to be present in the samples, 
 although at very low concentrations. Since most of these metabolites are isomers to the 
7-hydroxy metabolite, a highly selective method is therefore critical for the separation and 
accurate determination of warfarin and 7-hydroxywarfarin. Moreover, other interferences 
coming from the complex plasma matrix should be considered during method development.
Initial method development was carried out using a short C12 column (30 ´ 2 mm, 
4 mm, Synergi Max RP Phenomenex®) and a mobile phase of different ratios of acetonitrile 
and water. Although several compositions of mobile phase were experimented, warfarin 
and 7-hydroxywarfarin peaks eluted very close to each other and at early retention times 
where most of the polar plasma interferents were expected to elute. Therefore, it was de-
cided to use a more retentive C18 stationary phase and longer column (125 x 4.6 mm, 5 mm, 
LiChrospher Phenomenex®) which has resulted in a better separation and retention for 
both analytes. However, when standards of other metabolites (4-, 6- and 10-hydroxywar-
farin in addition to warfarin alcohol) and naproxen, as internal standard, were added to 
test the selectivity of the separation, some metabolites co-eluted with either warfarin or 
naproxen. Adjusting the mobile phase conditions or replacing naproxen with alternative 
internal standards did not produce a better separation.
In order to separate these structurally related analytes within a reasonable run time, 
we tried a stationary phase with different chemistry and higher selectivity for aromatic 
compounds like warfarin and its metabolites. Thus, a diphenyl column, with small particle 
size (150 × 4.6 mm, 3 μm, Fortis®) was tested. The phenyl-based stationary phase offers a 
different selectivity for aromatic compounds due to the p-p interactions between the elec-
tron-rich double bonds of warfarin and metabolites and stationary phase-phenyl moieties. 
A successful separation of all compounds was achieved in 20-min run time, as was demon-
strated by injecting a mixture of standard solution of warfarin, 7-hydroxywarfarin and 
naproxen in the presence of 4-, 6-, 7-, 10-hydroxywarfarin and warfarin alcohol (Fig. 2). The 
mobile phase used was phosphate buffer (25 mmol L–1)/methanol/acetonitrile (70:20:10, 
V/V/V) (pH 7.4) at a flow rate of 0.8 mL min–1. pH of the mobile phase was chosen based on 
349
A. Zayed et al.: Simultaneous determination of warfarin and 7-hydroxywarfarin in rat plasma by HPLC-FLD, Acta Pharm. 70 (2020) 
343–357.
 
optimization experiments, showing that acidic pH negatively affected the intensity of the 
fluorescence signal of warfarin and thus pH 7.4 was selected as an optimum pH. Table I 
gives chromatographic parameters.
Method validation
Linearity. – The method was linear for warfarin and 7-hydroxywarfarin in the concen-
tration range of 0.01–25 μg mL–1. R2 was 0.998 and 0.996 for warfarin and 7-hydroxywarfa-
rin, resp. (Table II). All samples tested and analysed were well within the calibration range 
of the method for both warfarin and 7-hydroxywarfarin (0–25 μg mL–1). No dilution was 
required as no samples were above the ULOQ.
Accuracy and precision. – The intra-day average relative error (er) and RSD were 10.4 and 
8.9 % for warfarin, resp., and 10.5 and 7.3 % for 7-hydroxywarfarin, resp. (Table II). Simi-
larly, the inter-day average inaccuracy (er) and imprecision (RSD) for warfarin and 7-hy-
droxywarfarin were 10.1 and 2.5 %, and 10.7 and 4.3 %, resp. (Table II). See Tables III and 
IV for values at each QC level.
Fig. 2. Representative HPLC chromatogram for a mixture of standards of warfarin (0.1 μg mL–1) and 
its main metabolites (7-hydroxywarfarin: 0.2 μg mL–1; warfarin alcohol: 0.1 μg mL–1; 4-, 6- and 10- 
hydroxywarfarin: 0.05 μg mL–1). Keys to the peaks: 4-OH – 4-hydroxywarfarin, 6-OH – 6-hydroxy-
warfarin, 7-OH – 7-hydroxywarfarin, 10-OH – 10-hydroxywarfarin, IS – internal standard (naproxen).












7-Hydroxywarfarin 1.35 9.7 3820 2.33
1.69 2.09
Warfarin 1.23 14.3 4592 3.94
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Table II. Model analytical parameters evaluated for the quantification of warfarin and 7-hydroxywarfarin
Analytical performance Warfarin 7-Hydroxywarfarin






Calibration range (μg mL–1) 0.01–25 0.01–25 
R2 ≥ 0.998 ≥ 0.996
LOD (μg mL–1) 0.003 0.003 
LLOQ (μg mL–1) 0.01 0.01 














RSD (%) er (%)
LLOQ 0.010 1.19E-02 9.7 19.0 1.19E-02 4.0 19.0
QC-low 0.050 5.27E-02 11.8 5.4 4.90E-02 3.1 –2.0
QC-mid 1.0 1.13 9.2 13.0 1.08 2.5 8.0
QC-high 20.0 19.0 5.0 –5.0 17.8 0.3 –11.0
a n = 6, b n = 18














RSD (%) er (%)
LLOQ 0.010 1.19E-02 8.2 19.0 1.15E-02 2.2 15.0
QC-low 0.050 5.24E-02 12.5 4.8 5.11E-02 5.5 2.2
QC-mid 1.00 1.15 3.9 15.0 1.15 5.0 15.0
QC-high 20.0 19.3 4.8 –3.5 18.0 4.6 –10.0
a n = 6, b n = 18
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Sensitivity. – LOD and LLOQ were 0.003 and 0.01 μg mL–1, resp., for both 7-hydroxy-
warfarin and warfarin (Table II). The method was found appropriate with RSD and er 
values at LLOQ equal to 4.0–9.7 % and 19.0 %, resp., for warfarin, and 2.2–8.2 % and 19.0 % 
resp., for 7-hydroxywarfarin (Tables III and IV).
Selectivity. – No endogenous interference from rat plasma was observed at the reten-
tion time for warfarin (tR 14.2 min), 7-hydroxywarfarin (tR 9.8 min), and IS (tR 11.8 min) 
(Fig. 3). The method was able to distinguish warfarin and 7-hydroxywarfarin from other 
metabolites (Fig. 2). These results demonstrate that the method has the required selectivity 
to quantify warfarin and 7-hydroxywarfarin in rat plasma. 
Carryover. – No analyte or internal standard peaks were observed in the blank samples 
injected following the highest standard concentration.
Application to the pharmacokinetic study
The validated HPLC-FLD method was applied successfully for simultaneous determi-
nation of warfarin and 7-hydroxywarfarin in plasma samples obtained from rats following 
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oral administration of single warfarin dose. Representative chromatogram for a plasma 
sample collected 24 h post warfarin administration, is shown in Fig. 4. The chromatogram 
demonstrates the selectivity and sensitivity of the method to analyze real samples and its 
suitability for performing PK studies of warfarin and 7-hydroxywarfarin in rats. Plasma 
concentration vs. time profiles of warfarin and 7-hydroxywarfarin after oral administra-
tion of 2.0 mg kg–1 of warfarin is shown in Fig. 5, and the main PK parameters are outlined 
in Table V. 
It was shown that Cmax of warfarin metabolite, 7-hydroxywarfarin, was about 2.3 % of 
respective Cmax of warfarin, with the lower rate of formation/appearance in the systemic 
Fig. 4. Representative HPLC chromatogram for warfarin, 7-hydroxywarfarin and internal standard 
in real plasma sample obtained 24 h after single oral administration of 2 mg kg–1 warfarin. Keys to 
the peaks: 6-OH – 6-hydroxywarfarin, 7-OH – 7-hydroxywarfarin, IS – internal standard (naproxen).
Table V. Pharmacokinetic parameters of warfarin and 
7-hydroxywarfarin after single oral administration of warfarin in SD ratsa
Pharmacokinetic parameter Warfarinb 7-Hydroxywarfarinb
Cmax (μg mL–1) 16.0 ± 2.4 0.36 ± 0.06
tmax (h) 3.0 ± 0.6 7.0 ± 0.7
AUC0µ  (μg h mL–1) 378.4 ± 66.6 10.3 ± 1.8
AUMC0µ (μg h2 mL–1) 10236 ± 2770 345 ± 87
MRT (h) 27.0 ± 5.0 33.0 ± 4.0
CL/F (mL h–1 kg–1) 6.0 ± 0.9 223.0 ± 35.0
Vd/F (mL kg–1) 292.0 ± 64.0 6409.0 ± 1832.0
t1/2 (h) 32.5 ± 5.0 21.0 ± 6.0
a Dose of warfarin: 2 mg kg–1. 
b Mean ± SEM (n = 6).
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circulation. This was indicated by ca 4-h increase in tmax compared to warfarin. The extent 
of warfarin bioavailability, represented by AUC0µ, was shown to be 38-fold higher than that 
of its metabolite. Shorter terminal t1/2 and higher apparent clearance was shown for 7-hy-
droxywarfarin, which resulted in the 21.9-fold larger apparent volume of distribution 
when compared to warfarin. These PK results are in agreement with reported PK results 
for warfarin and 7-hydroxywarfarin in rats (30) and demonstrate the reliability of the 
HPLC-FLD method for studying PK and metabolism of warfarin in rats.
Comparison of the described method with literature methods (Table VI) highlights 
the advantage of direct and simultaneous determination of warfarin and 7-hydroxywarfarin 
without the need for post-column manipulation or laborious sample derivatization which 
was required by previously published HPLC-FLD methods (28). The simplicity of liquid 
extraction combined with the isocratic reversed-phase conditions as opposed to normal 
phase (28), ion pair (27) or gradient elution (25) allows the method to lend itself readily to 
routine sample analysis such as in pharmacokinetic and animal studies. Moreover, the 
Fig. 5. Plasma concentration vs. time profiles of: a) warfarin, b) 7-hydroxywarfarin, following administra-
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economy, sensitivity and selectivity of the FLD detection make this method ideal for quan-
tifying warfarin and 7-hydroxywarfarin in complex matrices compared to the less sensi-
tive UV (16, 17, 19) and expensive MS detectors (23–25).
CONCLUSIONS
A new sensitive, selective, accurate and precise HPLC-FLD method has been developed 
and validated for the quantitation of warfarin and 7-hydroxywarfarin in rat plasma. The 
method demonstrated adequate sensitivity to quantify 0.01 μg mL–1 of both warfarin and 
7-hydroxywarfarin in only 100 μL plasma. The sensitivity and low instrument capital cost 
of the fluorescence detector combined with the unique selectivity of the diphenyl stationary 
phase make the method ideal for carrying out metabolic interaction studies of warfarin in 
small animals like rats. Quantification of 7-hydroxywarfarin will enable drug-to-drug and 
drug-to-diet interaction studies investigating altered warfarin metabolism and response 
because of various CYP2C9 phenotypes.
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